When the Exelon patch (rivastigmine, a cholinesterase inhibitor that slows but does not reverse dementia symptoms) seems to stop helping, the next step is not to quit — it is a structured reassessment, then one of four documented paths: switching to a different cholinesterase inhibitor, adding memantine, checking eligibility for newer anti-amyloid drugs, or a carefully monitored taper off the medication. Which path fits depends on the stage of the disease and whether the apparent failure is real. Families often judge failure by continued decline, but decline is expected even when the drug is working. Doctors therefore verify non-response first, then move deliberately through the options below rather than continuing the patch indefinitely by default.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Is the patch really failing, or does it just look that way?
- Switching to a different cholinesterase inhibitor
- Adding memantine in moderate-to-severe disease
- Do the new anti-amyloid drugs apply?
- When stopping is the right answer
- The decision pathway, in order
- Frequently Asked Questions
Is the patch really failing, or does it just look that way?
Because rivastigmine only slows decline, a patient can worsen while still benefiting. A review of rivastigmine therapeutic management published on PMC notes that guidelines call for reassessment before any switch: is the dose maximized, is the patch applied correctly and consistently, and is an intercurrent illness — such as a urinary tract infection — masquerading as drug failure? True non-response, by that review's definition, means documented lack or loss of efficacy on both cognition and daily function despite adequate dosing.
That documentation matters, because the later options each carry their own trade-offs. Practical checks before concluding the patch has failed:.
- Confirm the dose was titrated to the maximum tolerated strength.
- Verify the patch is applied daily, to clean dry skin, with the old one removed.
- Rule out new infections, medication changes, or hospitalization as the cause of a sudden drop.
- Compare today's function to three to six months ago, not to last week.
Switching to a different cholinesterase inhibitor
Failure on one cholinesterase inhibitor does not predict failure on another. In a 26-week open-label multicenter study reported in Primary Care Companion to the Journal of Clinical Psychiatry, patients declining on donepezil were switched to rivastigmine without a washout period; 56.2% were rated responders on the Clinicians' Global Impression of Change, and MMSE scores improved or stabilized in 48.9%.
The switch works in the other direction too — from the rivastigmine patch to donepezil or galantamine. Roughly half of non-responders benefiting from a swap is a meaningful enough rate that guidelines treat switching as a standard step, not a long shot. The switch is usually done directly or with a brief gap, under the prescriber's direction.
Adding memantine in moderate-to-severe disease
For patients who have progressed to moderate or severe Alzheimer's, adding memantine — a drug with a different mechanism, FDA-approved for that stage — is the standard next move. Current clinical practice guidelines for dementia strongly recommend memantine at this stage, often combined with a cholinesterase inhibitor like the Exelon patch.
The honest caveat: the combination evidence is mixed. The DOMINO-AD randomized trial, published in the New England Journal of Medicine, found no significant benefit of donepezil plus memantine over donepezil alone in moderate-to-severe Alzheimer's, and reviews conclude a robust effect of combination therapy remains undemonstrated. Memantine is still worth discussing, but families should expect modest gains at best.
Do the new anti-amyloid drugs apply?
Two disease-modifying antibodies now exist: lecanemab (Leqembi, approved by the FDA in July 2023) and donanemab (Kisunla, approved July 2024). According to the Alzheimer's Association, both are indicated only for early symptomatic Alzheimer's — mild cognitive impairment or mild dementia — with confirmed amyloid pathology on testing. That eligibility window excludes most patients who have already reached moderate or severe stages on rivastigmine.
But if the patch was started early and the person is still in mild disease, an evaluation is worth requesting promptly, because the window closes as the disease advances. Expectations should stay grounded: lecanemab slowed cognitive and functional decline by about 27% over 18 months versus placebo — slowing, not reversal. Dosing logistics have eased, with the FDA approving every-4-week maintenance dosing in January 2025 and a weekly subcutaneous auto-injector on August 29, 2025, per AJMC's coverage.
When stopping is the right answer
Withdrawing the patch is a legitimate medical decision, not giving up. The evidence-based deprescribing guideline from Australia's NHMRC Cognitive Decline Partnership Centre recommends withdrawing cholinesterase inhibitors or memantine through shared decision-making when treatment goals are no longer being met — for example, in severe or end-stage dementia where side effects like nausea, weight loss, or slow heart rate now outweigh any benefit.
Stopping should be a monitored trial, not an abrupt halt. The guideline's published summary advises halving the dose every four weeks down to the lowest strength, reviewing the person roughly every four weeks, and restarting the drug if they clearly worsen after withdrawal. A restart clause means the decision is reversible if the drug was doing more than it appeared.
The decision pathway, in order
Cleveland Clinic clinicians describe the documented sequence for a patch that "isn't helping": reassess first, then consider switching agents, then add memantine if the disease is moderate-to-severe, then evaluate anti-amyloid eligibility if still early-stage, and otherwise trial a tapered, monitored discontinuation. Bring a specific record to the appointment: when the patch started, current dose, what changed and when. A single documented example — "she stopped recognizing the kitchen in June, two months after the dose increase" — moves the conversation further than "it isn't working.".
- Reassess: confirm dosing, adherence, patch technique, and rule out illness.
- Switch: try donepezil or galantamine; about half of non-responders improve or stabilize.
- Add: discuss memantine for moderate-to-severe disease, with realistic expectations.
- Evaluate: ask about lecanemab or donanemab only if disease is still mild and amyloid-confirmed.
- Taper: if goals are no longer met, halve the dose every four weeks with scheduled reviews.
Frequently Asked Questions
How long should the Exelon patch be tried before deciding it isn't working?
Judge over months, not weeks, and only at the maximum tolerated dose. Guidelines define non-response as documented decline in both cognition and function despite adequate dosing.
Is it dangerous to stop the patch suddenly?
Abrupt stopping is not recommended. The deprescribing guideline advises halving the dose every four weeks with regular review, and restarting if the person clearly worsens.
Can someone on the Exelon patch get lecanemab or donanemab?
Only if they still have mild cognitive impairment or mild dementia with confirmed amyloid pathology. Moderate-to-severe disease falls outside the approved indication.
